Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment

Journal of Immunology

Volumn 200, Issue 1, 2018, Pages 347-354

  Gorris, Mark A J ^a   Halilovic, Altuna ^a,b   Rabold, Katrin ^a   Van Duffelen, Anne ^a   Wickramasinghe, Iresha N ^a   Verweij, Dagmar ^a,b   Wortel, Inge M N ^a   Textor, Johannes C ^a   De Vries, I Jolanda M ^a,b   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CD27 ANTIGEN; CD3 ANTIGEN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HAVCR2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TNFRSF4 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EIGHT COLOR MULTIPLEX IMMUNOHISTOCHEMISTRY; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PROCEDURES; SINGLE CELL ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CTLA-4 ANTIGEN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, OX40; SINGLE-CELL ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 85038568962     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1701262     Document Type: Article

References (43)

1. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
2. Robert, C., J. Schachter, G. V. Long, A. Arance, J. J. Grob, L. Mortier, A. Daud, M. S. Carlino, C. McNeil, M. Lotem, et al.; KEYNOTE-006 investigators. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372: 2521-2532.
3. Ribas, A., O. Hamid, A. Daud, F. S. Hodi, J. D. Wolchok, R. Kefford, A. M. Joshua, A. Patnaik, W. J. Hwu, J. S. Weber, et al. 2016. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315: 1600-1609.
4. Brahmer, J., K. L. Reckamp, P. Baas, L. Crinò, W. E. Eberhardt, E. Poddubskaya, S. Antonia, A. Pluzanski, E. E. Vokes, E. Holgado, et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373: 123-135.
5. Reck, M., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csöszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, et al; KEYNOTE-024 Investigators. 2016. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375: 1823-1833.
6. Ferris, R. L., G. Blumenschein, Jr., J. Fayette, J. Guigay, A. D. Colevas, L. Licitra, K. Harrington, S. Kasper, E. E. Vokes, C. Even, et al. 2016. Nivo-lumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375: 1856-1867.
7. Powles, T., J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. A. Burris, D. P. Petrylak, S. L. Teng, et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558-562.
8. Massard, C., M. S. Gordon, S. Sharma, S. Rafii, Z. A. Wainberg, J. Luke, T. J. Curiel, G. Colon-Otero, O. Hamid, R. E. Sanborn, et al. 2016. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34: 3119-3125.
9. Motzer, R. J., B. Escudier, D. F. McDermott, S. George, H. J. Hammers, S. Srinivas, S. S. Tykodi, J. A. Sosman, G. Procopio, E. R. Plimack, et al.; CheckMate 025 Investigators. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373: 1803-1813.
10. Nghiem, P. T., S. Bhatia, E. J. Lipson, R. R. Kudchadkar, N. J. Miller, L. Annamalai, S. Berry, E. K. Chartash, A. Daud, S. P. Fling, et al. 2016. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med. 374: 2542-2552.
11. Seiwert, T. Y., B. Burtness, R. Mehra, J. Weiss, R. Berger, J. P. Eder, K. Heath, T. McClanahan, J. Lunceford, C. Gause, et al. 2016. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17: 956-965.
12. Sharma, P., and J. P. Allison. 2015. The future of immune checkpoint therapy. Science 348: 56-61.
13. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264.
14. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. [Published erratum appears in 2011 J. Exp. Med. 208: 1331.] J. Exp. Med. 207: 2187-2194.
15. Guo, Z., D. Cheng, Z. Xia, M. Luan, L. Wu, G. Wang, and S. Zhang. 2013. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J. Transl. Med. 11: 215.
16. Kim, J. E., M. A. Patel, A. Mangraviti, E. S. Kim, D. Theodros, E. Velarde, A. Liu, E. W. Sankey, A. Tam, H. Xu, et al. 2017. Combination therapy with Anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin. Cancer Res. 23: 124-136.
17. He, L. Z., L. Thomas, J. Weidlick, L. Vitale, T. O'Neill, N. Prostak, K. Sundarapandiyan, H. Marsh, M. Yellin, T. A. Davis, and T. Keler. 2011. Development of a human Anti-CD27 antibody with efficacy in lymphoma and leukemia models by two distinct mechanisms. Blood 118: 2861.
18. Ramakrishna, V., K. Sundarapandiyan, B. Zhao, M. Bylesjo, H. C. Marsh, and T. Keler. 2015. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. J. Immunother. Cancer 3: 37.
19. Ahrends, T., N. Bąbała, Y. Xiao, H. Yagita, H. van Eenennaam, and J. Borst. 2016. CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination. Cancer Res. 76: 2921-2931.
20. Weinberg, A. D., M. M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164: 2160-2169.
21. Gough, M. J., C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg. 2008. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68: 5206-5215.
22. Piconese, S., B. Valzasina, and M. P. Colombo. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. [Published erratum appears in 2008 J. Exp. Med. 205: 1505.] J. Exp. Med. 205: 825-839.
23. Aspeslagh, S., S. Postel-Vinay, S. Rusakiewicz, J. C. Soria, L. Zitvogel, and A. Marabelle. 2016. Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer 52: 50-66.
24. Murtaza, A., H. Laken, J. D. S. Correia, P. McNeeley, L. Altobell, J. Zhang, P. Vancutsem, K. Wilcoxen, and D. Jenkins. 2016. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur. J. Cancer 69: S102.
25. Sanborn, R. E., M. J. Pishvain, M. K. Callahan, N. Rizvi, H. Kluger, M. Yellin, T. Rawls, L. Vitale, A. Halim, T. Davis, and T. Keler. 2016. Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. Cancer Res. 76: CT023.
26. Swart, M., I. Verbrugge, and J. B. Beltman. 2016. Combination approaches with immune-checkpoint blockade in cancer therapy. Front. Oncol. 6: 233.
27. van der Loos, C. M. 2008. Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. J. Histochem. Cytochem. 56: 313-328.
28. Ramos-Vara, J. A., and M. A. Miller. 2014. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry-the red, brown, and blue technique. Vet. Pathol. 51: 42-87.
29. Huang, W., K. Hennrick, and S. Drew. 2013. A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum. Pathol. 44: 29-38.
30. Stack, E. C., C. Wang, K. A. Roman, and C. C. Hoyt. 2014. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70: 46-58.
31. Feng, Z., S. Puri, T. Moudgil, W. Wood, C. C. Hoyt, C. Wang, W. J. Urba, B. D. Curti, C. B. Bifulco, and B. A. Fox. 2015. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J. Immunother. Cancer 3: 47.
32. Feng, Z., S. M. Jensen, D. J. Messenheimer, M. Farhad, M. Neuberger, C. B. Bifulco, and B. A. Fox. 2016. Multispectral imaging of T and B cells in murine spleen and tumor. J. Immunol. 196: 3943-3950.
33. Stack, E. C., P. G. Foukas, and P. P. Lee. 2016. Multiplexed tissue biomarker imaging. J. Immunother. Cancer 4: 9.
34. Kerstens, H. M. J., J. C. M. Robben, P. J. Poddighe, W. J. G. Melchers, H. Boonstra, P. C. M. de Wilde, M. V. E. Macville, and A. G. J. M. Hanselaar. 2000. AgarCyto: a novel cell-processing method for multiple molecular diagnostic analyses of the uterine cervix. J. Histochem. Cytochem. 48: 709-718.
35. The Medical Research Involving Human Subjects Act (WMO, Wet medisch-wetenschappelijk onderzoek met mensen). Available at: http://www.ccmo.nl/en/non-wmo-research. Accessed: September 15, 2016.
36. Shi, S. R., C. Liu, and C. R. Taylor. 2007. Standardization of immunohisto-chemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J. Histochem. Cytochem. 55: 105-109.
37. Lawrence, M. S., P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis, A. Sivachenko, S. L. Carter, C. Stewart, C. H. Mermel, S. A. Roberts, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
38. Tumeh, P. C., C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. M. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
39. Blank, C. U., J. B. Haanen, A. Ribas, and T. N. Schumacher. 2016. CANCER IMMUNOLOGY. The "cancer immunogram". Science 352: 658-660.
40. Gnjatic, S., V. Bronte, L. R. Brunet, M. O. Butler, M. L. Disis, J. Galon, L. G. Hakansson, B. A. Hanks, V. Karanikas, S. N. Khleif, et al. 2017. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J. Immunother. Cancer 5: 44.
41. Madore, J., R. E. Vilain, A. M. Menzies, H. Kakavand, J. S. Wilmott, J. Hyman, J. H. Yearley, R. F. Kefford, J. F. Thompson, G. V. Long, et al. 2015. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 28: 245-253.
42. Boddupalli, C. S., N. Bar, K. Kadaveru, M. Krauthammer, N. Pornputtapong, Z. Mai, S. Ariyan, D. Narayan, H. Kluger, Y. Deng, et al. 2016. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight 1: e88955.
43. Mansfield, A. S., S. J. Murphy, T. Peikert, E. S. Yi, G. Vasmatzis, D. A. Wigle, and M. C. Aubry. 2016. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin. Cancer Res. 22: 2177-2182.